$MD
Pediatrix Medical Group, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023057738 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $496.4M $506.6M
YoY Change -3.39% 3.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $416.7M $425.8M
YoY Change -0.23% 6.26%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.062M $9.211M
YoY Change -0.81% 2.85%
% of Gross Profit
Operating Expenses $457.4M $466.3M
YoY Change -0.18% 5.38%
Operating Profit $40.27M
YoY Change -15.01%
Interest Expense -$7.360M $10.37M
YoY Change -10.4% 9.02%
% of Operating Profit 25.76%
Other Income/Expense, Net -$9.440M
YoY Change 10.69%
Pretax Income -$138.9M $30.83M
YoY Change -599.03% -20.66%
Income Tax -$14.56M $9.441M
% Of Pretax Income 30.62%
Net Earnings -$124.3M $21.39M
YoY Change -519.05% -30.39%
Net Earnings / Revenue -25.04% 4.22%
Basic Earnings Per Share $0.26
Diluted Earnings Per Share -$1.51 $0.26
COMMON SHARES
Basic Shares Outstanding 84.02M 83.94M
Diluted Shares Outstanding 82.95M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $177.7M $124.7M
YoY Change 72.46% 24.64%
Cash & Equivalents $73.26M $21.18M
Short-Term Investments $104.5M $103.5M
Other Short-Term Assets $12.31M $7.866M
YoY Change -7.19% -20.54%
Inventory
Prepaid Expenses $13.53M $10.59M
Receivables $272.3M $277.4M
Other Receivables $7.565M $0.00
Total Short-Term Assets $483.5M $420.5M
YoY Change 12.96% -0.75%
LONG-TERM ASSETS
Property, Plant & Equipment $75.64M $75.15M
YoY Change 3.21% 4.87%
Goodwill $1.380B $1.532B
YoY Change -9.8% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $82.17M $108.0M
YoY Change -33.29% -8.25%
Total Long-Term Assets $1.736B $1.906B
YoY Change -9.56% -0.13%
TOTAL ASSETS
Total Short-Term Assets $483.5M $420.5M
Total Long-Term Assets $1.736B $1.906B
Total Assets $2.220B $2.326B
YoY Change -5.45% -0.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $34.59M $31.70M
YoY Change 8.57% 16.8%
Accrued Expenses $337.3M $292.7M
YoY Change -7.33% -3.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $14.91M $14.93M
YoY Change 0.1% 0.07%
Total Short-Term Liabilities $388.9M $350.4M
YoY Change -8.91% -0.36%
LONG-TERM LIABILITIES
Long-Term Debt $618.4M $621.7M
YoY Change -2.82% -14.95%
Other Long-Term Liabilities $30.55M $31.19M
YoY Change -22.48% -26.62%
Total Long-Term Liabilities $30.55M $31.19M
YoY Change -22.48% -26.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $388.9M $350.4M
Total Long-Term Liabilities $30.55M $31.19M
Total Liabilities $1.371B $1.358B
YoY Change -5.87% -7.8%
SHAREHOLDERS EQUITY
Retained Earnings $149.5M -$25.18M
YoY Change -267.83% -78.79%
Common Stock $1.001B $996.7M
YoY Change 1.66% 1.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $849.1M $968.0M
YoY Change
Total Liabilities & Shareholders Equity $2.220B $2.326B
YoY Change -5.45% -0.24%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$124.3M $21.39M
YoY Change -519.05% -30.39%
Depreciation, Depletion And Amortization $9.062M $9.211M
YoY Change -0.81% 2.85%
Cash From Operating Activities $69.25M $79.94M
YoY Change -29.83% -4.07%
INVESTING ACTIVITIES
Capital Expenditures $9.044M $9.154M
YoY Change -0.15% -231.77%
Acquisitions
YoY Change
Other Investing Activities -$3.380M -$4.850M
YoY Change 54.83% -664.61%
Cash From Investing Activities -$12.42M -$14.00M
YoY Change 10.52% 130.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.747M -50.60M
YoY Change -94.5% -38.78%
NET CHANGE
Cash From Operating Activities 69.25M 79.94M
Cash From Investing Activities -12.42M -14.00M
Cash From Financing Activities -4.747M -50.60M
Net Change In Cash 52.08M 15.33M
YoY Change 4405.1% -382.84%
FREE CASH FLOW
Cash From Operating Activities $69.25M $79.94M
Capital Expenditures $9.044M $9.154M
Free Cash Flow $60.21M $70.78M
YoY Change -32.83% -21.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-12111
dei Entity Registrant Name
EntityRegistrantName
Pediatrix Medical Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
FL
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3667538
dei Entity Address Address Line1
EntityAddressAddressLine1
1301 Concord Terrace
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunrise
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33323
dei City Area Code
CityAreaCode
954
dei Local Phone Number
LocalPhoneNumber
384-0175
dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
dei Trading Symbol
TradingSymbol
MD
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
84023916
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21179000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9824000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
103541000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
93239000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
277352000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
296787000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10586000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14878000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
7866000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13261000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
420524000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
427989000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75146000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73290000
CY2023Q3 us-gaap Goodwill
Goodwill
1532092000
CY2022Q4 us-gaap Goodwill
Goodwill
1532092000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15486000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18491000
CY2023Q3 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
72443000
CY2022Q4 md Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
66924000
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
102638000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
105925000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108010000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
123176000
CY2023Q3 us-gaap Assets
Assets
2326339000
CY2022Q4 us-gaap Assets
Assets
2347887000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
302583000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
374225000
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14929000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
14898000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21814000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21589000
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11118000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
16271000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
350444000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
426983000
CY2023Q3 us-gaap Line Of Credit
LineOfCredit
0
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
4000000
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
621691000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
632381000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
48489000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44213000
CY2023Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
265523000
CY2022Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
275629000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
41018000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
33638000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
31189000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39411000
CY2023Q3 us-gaap Liabilities
Liabilities
1358354000
CY2022Q4 us-gaap Liabilities
Liabilities
1456255000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83929000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83929000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
838000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82947000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82947000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
839000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
829000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
995847000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
983601000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3517000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3735000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25184000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89063000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
967985000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
891632000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2326339000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2347887000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
506612000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
489915000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1498197000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1458177000
CY2023Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
368404000
CY2022Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
342850000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1084671000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1016762000
CY2023Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31319000
CY2022Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
31857000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
93128000
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
90189000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57406000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57888000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
174478000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
180340000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9211000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8956000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27109000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26500000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
977000
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
7736000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
466340000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
442528000
us-gaap Operating Expenses
OperatingExpenses
1379386000
us-gaap Operating Expenses
OperatingExpenses
1321527000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
40272000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
47387000
us-gaap Operating Income Loss
OperatingIncomeLoss
118811000
us-gaap Operating Income Loss
OperatingIncomeLoss
136650000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
273000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
617000
us-gaap Investment Income Net
InvestmentIncomeNet
2096000
us-gaap Investment Income Net
InvestmentIncomeNet
2336000
CY2023Q3 us-gaap Interest Expense
InterestExpense
10374000
CY2022Q3 us-gaap Interest Expense
InterestExpense
9516000
us-gaap Interest Expense
InterestExpense
31994000
us-gaap Interest Expense
InterestExpense
29743000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
661000
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
371000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1578000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1319000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9440000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8528000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28320000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-83104000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
30832000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
38859000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
90491000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
53546000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9441000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10051000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26612000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14982000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
21391000
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
28808000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
63879000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
38564000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
1920000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1892000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
21391000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
30728000
us-gaap Profit Loss
ProfitLoss
63879000
us-gaap Profit Loss
ProfitLoss
36672000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-4000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
21391000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
30728000
us-gaap Net Income Loss
NetIncomeLoss
63879000
us-gaap Net Income Loss
NetIncomeLoss
36676000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
0
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
508000
us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
100000
us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
1816000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1515000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
218000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-5417000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21392000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
29213000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
64097000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
31259000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82543000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82126000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82127000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84122000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82950000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82776000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82492000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84821000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
891632000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
14206000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
604000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1095000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3009000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
775000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
909771000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
28282000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-387000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1594000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3126000
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
11000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
942375000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
21391000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1187000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3164000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
133000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
967985000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
896692000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21188000
CY2022Q1 md Dissolution Of And Net Income Loss Attributable To Noncontrolling Interest
DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest
-203000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2668000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1174000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4435000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1166000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
877076000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
27136000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1234000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1664000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5186000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
64398000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
845430000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
30728000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1515000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1381000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4120000
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
21477000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
858667000
us-gaap Net Income Loss
NetIncomeLoss
63879000
us-gaap Net Income Loss
NetIncomeLoss
36676000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-1892000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27109000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26500000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1015000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1346000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57016000
us-gaap Share Based Compensation
ShareBasedCompensation
9299000
us-gaap Share Based Compensation
ShareBasedCompensation
12891000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10589000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8702000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1607000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2379000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-22095000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
501000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4290000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-22709000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-13343000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-11160000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-56118000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-76439000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5154000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
799000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
7360000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-16500000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-10309000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
73078000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
80019000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-5003000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-11764000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
68075000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
68255000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1667000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
28167000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
26477000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
14938000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
16560000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
15889000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
24284000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
20650000
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
116000
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
2153000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35752000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45713000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
470000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
674500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
474000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
579500000
md Payments To Term Loan
PaymentsToTermLoan
9375000
md Payments To Term Loan
PaymentsToTermLoan
6250000
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
0
us-gaap Repayments Of Senior Debt
RepaymentsOfSeniorDebt
1046880000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
650000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
8621000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
2105000
md Repayments Of Long Term Capital Lease Obligation
RepaymentsOfLongTermCapitalLeaseObligation
2176000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3876000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4220000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
919000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
87041000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-8445000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
483000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20968000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-401265000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11355000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-378723000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9824000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
387391000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21179000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8668000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
103541000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93239000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
84821000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
888000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1201000
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1448620000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1548492000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1171268000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1251705000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
277352000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
296787000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
506612000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
489915000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1498197000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1458177000
CY2023Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2022Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
31696000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31857000
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
150014000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
197831000
CY2023Q3 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
35366000
CY2022Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
34983000
CY2023Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
30169000
CY2022Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
32232000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3204000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
8921000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52134000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
68401000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
302583000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
374225000
md Increase Decrease In Accrued Salaries And Bonuses
IncreaseDecreaseInAccruedSalariesAndBonuses
47800000
CY2023Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.05375
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
us-gaap Debt Instrument Description
DebtInstrumentDescription
Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2023Q3 md Purchase Price
PurchasePrice
1.01
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82543000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82126000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82127000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
84122000
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
407000
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
650000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
365000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
699000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82950000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82776000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82492000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
273000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9300000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12900000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2018Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000
CY2018Q3 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
5500000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-057738-index-headers.html Edgar Link pending
0000950170-23-057738-index.html Edgar Link pending
0000950170-23-057738.txt Edgar Link pending
0000950170-23-057738-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img259349275_0.jpg Edgar Link pending
md-20230930.htm Edgar Link pending
md-20230930.xsd Edgar Link pending
md-ex31_1.htm Edgar Link pending
md-ex31_2.htm Edgar Link pending
md-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
md-20230930_def.xml Edgar Link unprocessable
md-20230930_cal.xml Edgar Link unprocessable
md-20230930_lab.xml Edgar Link unprocessable
md-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
md-20230930_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending